SeTD2-IN-1 TFA manufacturers
- EZM0414 TFA
-
- $163.00
-
2026-07-15
- CAS:2411759-92-5
- Purity: 98.88%
- Supply Ability: 10g
|
| | SeTD2-IN-1 TFA Basic information |
| | SeTD2-IN-1 TFA Chemical Properties |
| storage temp. | 4°C, away from moisture | | solubility | DMSO : 200 mg/mL (388.72 mM; Need ultrasonic) | | form | Solid | | color | White to light yellow |
| | SeTD2-IN-1 TFA Usage And Synthesis |
| Uses | EZM0414 TFA is the TFA salt form of EZM0414 (HY-144858). EZM0414 TFA is a potent, selective, orally active inhibitor of SETD2 (IC50=18 nM in SETD2 biochemical assay; IC50=34 nM in cellular assay). EZM0414 TFA can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma[1]. | | Biological Activity | SETD2-IN-1 TFA is a potent, selective and orally active inhibitor of SETD2 which is a human histone methyltransferase. SETD2-IN-1 TFA has anti-proliferative effects[1]. | | in vivo | EZM0414 (15 and 30 mg/kg, p.o., twice a day for 35 days) inhibits tumor growth in NOD SCID mouse xenograft model implanted with human KMS-11 cells, and is well-tolerated[3].
EZM0414 (50 mg/kg, p.o.) shows almost 100% oral bioavailability in rats and mice, t1/2 of 1.8 h (mice)and 3.8 h (rats)[3].| Animal Model: | KMS-11 Xenograft mouse models[3] | | Dosage: | 15-30 mg/kg | | Administration: | po, twice a day for 35 days | | Result: | Inhibited tumor growth. |
| | IC 50 | SETD2/KMT3A | | References | [1]. John Lampe, et al. Substituted indoles and methods of use thereof. WO2020037079A1. |
| | SeTD2-IN-1 TFA Preparation Products And Raw materials |
|